When to Start Mannitol in Intracerebral Hemorrhage
Mannitol should be initiated when there are clinical signs of threatened intracranial hypertension or brain herniation (such as pupillary abnormalities, decerebrate posturing, or neurological deterioration not attributable to systemic causes), but NOT routinely or prophylactically in patients with ICH who lack these signs.
Evidence-Based Timing and Indications
Clear Indications for Mannitol Use
Mannitol is recommended specifically for:
- Acute intracranial hypertensive crisis with documented or clinically evident elevated ICP 1
- Signs of impending brain herniation including mydriasis, anisocoria, or acute neurological worsening 1
- Documented elevated ICP (>20-25 mmHg if monitoring is in place) 2, 3
The 2018 traumatic brain injury guidelines provide the strongest recommendation: mannitol 20% at a dose of 250 mOsm should be infused over 15-20 minutes to treat threatened intracranial hypertension or signs of brain herniation after controlling secondary brain insults 1.
When NOT to Use Mannitol
Prophylactic administration is not indicated 2. Multiple lines of evidence demonstrate potential harm:
- A 2018 meta-analysis found that improper mannitol use within 24 hours of ICH onset may increase the incidence of early hematoma enlargement 4
- A Chinese study showed that mannitol use within 24 hours in patients with mild intracranial hypertension led to significantly higher rates of hematoma enlargement (30% vs 9%, P<0.01) and worse neurological outcomes 5
- The INTERACT2 analysis found no overall benefit from mannitol in acute ICH, with propensity-matched odds ratio of 0.90 (95% CI 0.75-1.09, P=0.30) 6
- Recent 2026 data showed prolonged prophylactic mannitol was associated with increased perihemorrhagic edema growth and trended toward worse outcomes 7
Dosing Algorithm
When mannitol is indicated:
- Standard dose: 0.25-1 g/kg as 10-20% solution over 20-30 minutes 8, 9
- Acute crisis: Up to 1 g/kg over 15 minutes for acute intracranial hypertensive crisis 8
- Repeat dosing: May repeat once or twice as needed, provided serum osmolality remains <320 mOsm/L 2, 3, 9
Critical Monitoring Requirements
Before and during mannitol administration, assess:
- Renal function: Avoid in established anuria or severe renal disease 9
- Volume status: Exclude hypovolemia before use 3
- Serum osmolality and sodium: Target osmolality <320 mOsm/L; sodium <160 mmol/L 2, 1
- Cardiovascular status: Contraindicated in severe pulmonary edema or progressive heart failure 9
Special Considerations for ICH
The Canadian Stroke Best Practice guidelines emphasize that patients should be assessed for clinical signs of increased intracranial pressure before treatment 10. This assessment-first approach is critical because:
- Small hematomas (<30 mL) without significant mass effect have no indication for routine osmotic therapy 11
- For larger ICH (>30 mL) with symptomatic perihematomal edema, maintaining serum sodium at 140-150 mEq/L for 7-10 days may be beneficial, but this doesn't require mannitol 11
Alternative: Hypertonic Saline
At equiosmolar doses (~250 mOsm), hypertonic saline may be equally or more effective than mannitol for treating elevated ICP 3, 1. A 2011 meta-analysis suggested hypertonic saline is more effective than mannitol for acutely elevated ICP 12. Consider hypertonic saline as an alternative, particularly in patients with renal impairment where mannitol's diuretic effect is problematic.
Common Pitfalls to Avoid
- Do not use mannitol prophylactically in patients without signs of elevated ICP or herniation
- Do not administer within the first 24 hours unless there are clear signs of herniation or documented elevated ICP
- Do not continue beyond serum osmolality of 320 mOsm/L - risk of renal failure increases 2, 9
- Do not use in patients with small hematomas and mild symptoms - risk may outweigh benefit 4, 5
- Always use a filter when infusing 25% mannitol and warm crystallized solutions before use 8, 9